1. Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma
- Author
-
Sarah Earl, Joe Rahamim, Dennis Yiannakis, Siva Shivasankar, Ioannis Gounaris, and Bruce Lyons
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Dacarbazine ,Docetaxel ,Fatal Outcome ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Temozolomide ,Carcinoma ,medicine ,Humans ,Pharmacology (medical) ,Lung cancer ,Pharmacology ,Cisplatin ,business.industry ,Large cell ,Middle Aged ,Large cell neuroendocrine carcinoma of the lung ,medicine.disease ,Carcinoma, Neuroendocrine ,Quality of Life ,Carcinoma, Large Cell ,Female ,Taxoids ,business ,medicine.drug - Abstract
At present, there is no clear consensus on the most appropriate treatment approach for large cell neuroendocrine carcinoma of the lung. Large cell neuroendocrine carcinoma lesions differ from other nonsmall cell lung carcinomas in that they have a particularly aggressive clinical behaviour and extremely poor prognosis. We report a 52-year-old woman large cell neuroendocrine carcinoma patient with progressive stage IV disease in the chest, liver, adrenal glands and, particularly, the brain, who achieved a marked response to a fourth-line combination of docetaxel, cisplatin and temozolomide. This regimen significantly improved her quality of life and survival. The good response obtained in this heavily pretreated patient adds to the evidence regarding the use of temozolomide in patients with lung cancer with brain metastases.
- Published
- 2007
- Full Text
- View/download PDF